Gilead's remdesivir has 'little or no effect' on COVID-19 recovery or mortality: WHO Hey, biopharma: JPM isn't the be-all, end-all for dealmaking, Sanofi exec says CVS, Walgreens make deal with Trump admin to quickly distribute COVID-19 vaccines to nursing homes Pfizer CEO, facing pushback, shifts COVID vaccine timeline to late November Merck CEO calls on private industry to 'stabilize society' amid racial injustice, economic downturn BCBSA: Millennials' mental health is on the decline—and COVID-19 is making it worse NIH launches COVID-19 test of J&J, Bristol Myers and AbbVie anti-inflammatory drugs BARDA taps Beckman Coulter to develop a blood test for MIS-C, the severe childhood illness linked to COVID-19 Healthcare roundup: CMS data shows 21% of Medicare beneficiaries forego care Biopharma roundup: Russia greenlights remdesivir to treat COVID-19 Featured Story | By Arlene Weintraub The World Health Organization is raising doubts about the rapid emergency authorization of Gilead Sciences' antiviral remdesivir for treating COVID-19. A large international trial of hospitalized patients found the drug does not lessen the need for ventilation, shorten the length of hospital stays or save lives, the agency said. read more |
| |
|---|
|
| | Researchers studying COVID-19 are using metabolomics to get closer to the phenotype Seven months since the rapid progression of COVID-19 (SARS-CoV-2), researchers across the globe have moved at a breathtaking pace to understand the progression of the disease and develop effective treatments. Join us for a panel discussion with practitioners who’ve incorporated metabolomics in a range of COVID-19 related studies as they share their perspectives on findings from recently or soon-to-be published studies. Register Today. |
Top Stories By Amirah Al Idrus Among the many things we took for granted before COVID-19 were in-person gatherings, where everyone in biopharma could catch up, talk shop and maybe emerge with a new partner or two. Sanofi isn’t sweating it, though—the sudden need to go virtual gave companies a chance to get out of their dealmaking comfort zone. read more By Robert King Pharmacy chains CVS Health and Walgreens reached a deal with the Trump administration to distribute COVID-19 vaccines directly to nursing homes at no out-of-pocket charge. read more By Angus Liu Pfizer CEO Albert Bourla recently suggested the company would know whether its BioNTech-shared COVID-19 vaccine works by October. Criticism ensued. Now finding himself alone in the biopharma world with that bullish estimate, the Big Pharma chief is changing his tone. read more By Kyle Blankenship In a tumultuous 2020, the COVID-19 pandemic and simmering racial protests have exposed gaps between the ideal America some of its citizens see and the real America on the ground. Few voices have captured that difference more clearly than Merck CEO Ken Frazier—and now Frazier is calling on corporate America to take a stand. read more By Paige Minemyer Millennials' health is on the decline, due in large part to rising rates of several behavioral health conditions, according to a new report. read more By Angus Liu The search for effective COVID-19 drugs presses on as the National Institutes of Health launches a new trial of three immune modulator drugs in hospitalized patients. The new phase 3 study will include Johnson & Johnson’s Remicade, Bristol Myers Squibb’s arthritis med Orencia and AbbVie's experimental ceniciviroc alongside Gilead's remdesivir. read more By Conor Hale Beckman Coulter was awarded a contract from the U.S. Biomedical Advanced Research and Development Authority to develop a rapid diagnostic test for children that have a rare but serious reaction to the virus that causes COVID-19. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner The NIH picked drugs from J&J, BMS and AbbVie for a phase 3 trial in hospitalized patients. Russia approved remdesivir to treat COVID-19. Sanofi's partnership exec isn't sweating the lack of in-person meetings during the pandemic. Beckman Coulter is developing a childhood COVID-19 test, and Cue Health won a DOD contract to scale diagnostic production. read more |
